Most prostate cancers are androgen-sensitive malignancies whose growths depend on the
transcriptional activity of the androgen receptor (AR). In the 1940s, Charles Huggins …

The phosphatidylinositol‐3 kinase (PI3K)–AKT pathway is one of the most commonly
dysregulated pathways in all of cancer, with somatic mutations, copy number alterations …

Abstract PI3K/AKT signalling is commonly disrupted in human cancers, with AKT being a
central component of the pathway, influencing multiple processes that are directly involved …

Efficacy of Enzalutamide (ENZ) in castration resistant prostate cancer (CRPC) patients is
short-lived. Immunotherapy like T cell checkpoint blockade may improve patient survival …

Prostate cancer is a leading cause of cancer-related death in men worldwide. Aberrant
signaling in the androgen pathway is critical in the development and progression of prostate …

While the antiandrogen enzalutamide (Enz) extends the castration resistant prostate cancer
(CRPC) patients' survival an extra 4.8 months, it might also result in some adverse effects via …

Prostate cancer (PCa) is the most common cancer in men. The androgen receptor (AR) has
a pivotal role in the pathogenesis and progression of PCa. Many therapies targeting AR …

Androgen receptor (AR) is a validated drug target for prostate cancer based on its role in
proliferation, survival, and metastases of prostate cancer cells. Unfortunately, despite recent …

Simple Summary Prostate cancer can develop under hormone treatment and chemotherapy
from a castration-sensitive towards a castration-resistant into a drug resistant-tumor. The …

Abstract The PI3K/AKT/mTOR pathway is frequently activated in advanced prostate cancer,
due to loss of the tumour suppressor PTEN, and is an important axis for drug development …